Catherine Skari

WORLD HEPATITIS DAY 2020: Towards a ”Hepatitis-free Future”

World Hepatitis Day is commemorated each year on 28 July to enhance awareness of viral hepatitis, an inflammation of the…

Read More »

THOUGHTS ABOUT ME AND MY DAUGHTER by Melissa Basberber

´´Today I was asked to answer a survey and participate in an interview about how is it like to live…

Read More »

Oxford vaccine: Early Trials Show Promising Results that Suggest “Double Protection” from Coronavirus

The experimental vaccine being developed by AstraZeneca and Oxford University against the new coronavirus produced an immune response in early-stage…

Read More »

TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies

The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both…

Read More »

Early-Stage Trial Data on Oxford University COVID-19 Vaccine to be Published July 20

Early-stage human trial data on a vaccine being developed by Oxford University and AstraZeneca will be published on July 20, The…

Read More »

COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation

Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the…

Read More »

TIF Postpones its International Conference on Thalassaemia to 2021

Being mindful of the COVID-19 situation and wanting to ensure participants’ safety, TIF has taken the decision to postpone its long-awaited…

Read More »

Coronavirus Disease among Persons with Sickle Cell Disease

Individuals with sickle cell disease (SCD) are a particularly vulnerable group of patients, with a higher risk of severe complications…

Read More »

TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices

The safety concerns linked to the use of DEHP plasticizers, a manufactured chemical common in blood bags and PVC intravenous…

Read More »

GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (Voxelotor) to Treat Sickle Cell Patients in Europe

Global Blood Therapeutics (GBT) plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Oxbryta (Voxelotor) be approved…

Read More »